NCT06716645 - A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin | Biotech Hunter

Enrollment

244

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

February 14, 2025

Study Completion Date

February 14, 2025

Conditions

Common ColdCough

Interventions

DRUG

Robitussin Maximum Strength Cough and Chest Congestion DM

Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg

DRUG

Robitussin Maximum Strength Cough and Chest Congestion DM

Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg

DRUG

Robitussin Maximum Strength Nighttime Cough DM

Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg

Trial Locations (1)

Lindus Health Limited, New York

All Listed Sponsors

lead

HALEON

INDUSTRY